MARY LOCKE: Open Payments
NPI 1376930404 · AUSTELL, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$732 in 36 payments from 9 companies in 2025. Trend: 2023 $644 · 2024 $626 · 2025 $732
Food & beverage: $732
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $216 |
| GENZYME CORPORATION | 10 | $202 |
| BioCryst US Sales Co., LLC | 2 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $65 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $57 |
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Amgen Inc. | 1 | $19 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, TEZSPIRE, ORLADEYO, NEFFY, XOLAIR, Sajazir.
Industry payments across GA — which companies pay providers there.
